1. Home
  2. FGBI vs SPRO Comparison

FGBI vs SPRO Comparison

Compare FGBI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$9.49

Market Cap

151.6M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.55

Market Cap

135.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGBI
SPRO
Founded
1934
2013
Country
United States
United States
Employees
346
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.6M
135.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FGBI
SPRO
Price
$9.49
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.7K
405.8K
Earning Date
04-27-2026
05-13-2026
Dividend Yield
0.44%
N/A
EPS Growth
N/A
111.81
EPS
N/A
0.15
Revenue
N/A
$66,802,000.00
Revenue This Year
$567.70
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
$17.10
Revenue Growth
N/A
39.24
52 Week Low
$4.31
$0.65
52 Week High
$10.08
$3.09

Technical Indicators

Market Signals
Indicator
FGBI
SPRO
Relative Strength Index (RSI) 52.80 48.31
Support Level $9.32 $2.15
Resistance Level $10.03 $2.70
Average True Range (ATR) 0.45 0.11
MACD -0.02 -0.03
Stochastic Oscillator 63.58 28.16

Price Performance

Historical Comparison
FGBI
SPRO

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: